Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neflamapimod in Primary Progressive Aphasia (PPA)
NCT07033481Phase 2Active, not recruiting
- Sponsor
- CervoMed
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of neflamapimod in primary progressive aphasia (PPA), sponsored by CervoMed. Started Oct 2025; status: active, not recruiting.
02
Drugs
neflamapimod
03
Conditions
primary progressive aphasia (PPA)
Beyond the preview
Go deeper on NCT07033481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033481.